Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
September 27 2021 - 8:05AM
Business Wire
- Dr. Kjems is a leading global physician
scientist with a proven pharma track record of drug development
across multiple therapeutic areas, including chronic indications,
oncology and rare diseases -
- Gerald F. Cox, MD, PhD will continue offering
clinical development leadership, worldwide regulatory expertise and
access to expansive network as a member of the Company’s Scientific
Advisory Board -
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or
the “Company”), a clinical stage biotechnology company dedicated to
developing life-changing medicines through science and innovation
for patients and families living with diseases, today announced the
appointment of Lise Lund Kjems, MD, PhD as Chief Medical Officer.
Gerald F. Cox, MD, PhD, who has served as the Company’s Acting
Chief Medical Officer in a consultant role since March 2021, has
been appointed to the Company’s Scientific Advisory Board
(SAB).
Dr. Kjems is a well-established medical executive with over 20
years of preclinical and clinical development experience. As a
physician scientist, she has held leadership roles of increasing
responsibility for global groups of MDs, clinical
pharmacologist/scientists in early and late-stage clinical
development, PV/Drug Safety, Clinical Operations and Biostatistics.
Over the course of her career, she has amassed a broad range of
experience across multiple therapeutic areas in a diversified
portfolio of chronic indications, rare and ultra-rare diseases, as
well as oncology.
“We are thrilled to have Dr. Kjems join as our Chief Medical
Officer, to lead and execute the clinical and medical activities
for Cyclo Therapeutics. Her recent achievements and proven track
record to deliver end-to-end drug development for multiple
programs, including leadership roles at Novartis, Johnson &
Johnson, and Eli Lilly will have an immediate impact of the Company
and our clinical operations,” commented N. Scott Fine, CEO of Cyclo
Therapeutics. “We believe Dr. Kjems’ extensive expertise in running
successful clinical programs will prove to be invaluable as we
continue to advance Trappsol® Cyclo™ in our ongoing Phase 3
TransportNPC study for the treatment of Niemann-Pick Disease Type C
and as we look to initiate our Phase 2 study in Alzheimer’s
Disease.”
Prior to joining Cyclo Therapeutics, Dr. Kjems served as the
Vice President, Head of Clinical Development at Albireo Pharma
where she was responsible for leading end-to-end drug development
process for rare hepatic cholestatic diseases and other hepatic
diseases, culminating with the recent FDA and EMA approvals of
Bylvay™ (odevixibat) for Progressive Familial Intrahepatic
Cholestasis. Prior to that, she served as the Vice President,
Clinical Development at Aldeyra Therapeutics and Executive Medical
Director at Intarcia Therapeutics. From 2005 – 2014 she served in a
number or roles at Novartis, including Global Program Medical
Director/Medical Brand Director, where she was accountable for the
global clinical strategy and led clinical teams; two programs in
special metabolism, one rare indication and a program in secondary
hypogonadism and served as the clinical lead on study in NAFDL and
designed a clinical program for NAFLD and NASH. Additionally, she
served as Senior Global Program Diagnostic Executive Director,
Molecular Diagnostics and Executive Director, Deputy Head of
Translational Medicine, Diabetes/Metabolism during her tenure at
Novartis. Career appointments also include Executive Director,
Project Team Leader - 113715, PTP-1B Antisense Inhibitor and the
ApoB 100 inhibitor Programs at Ionis Pharmaceuticals (formerly Isis
Pharmaceuticals); Group Director, Clinical Drug Evaluation at
Johnson & Johnson; and Senior Clinical Pharmacologist, Clinical
Research at Eli Lilly.
“I am honored to be joining Cyclo Therapeutics and am excited by
this opportunity in my career. It is rare to come across the
combination of a proven platform technology with such compelling
data and a management team that is as dedicated to developing novel
therapies for such debilitating diseases and to serve the patient
communities as Cyclo Therapeutics. I believe this represents a very
unique opportunity by effectively advancing the clinical programs,
to potentially impact the etiology of the underlying diseases, with
the prospect of serving high unmet medical needs. I am very much
looking forward to this special opportunity and to have an impact
on the patient and physician communities. It is a privilege to be
working with the team to lead the advancement of these important
clinical programs,” stated Dr. Kjems, Chief Medical Officer of
Cyclo Therapeutics.
Dr. Kjems received her MD, and her PhD from the University of
Copenhagen Medical Faculty Denmark. She was an invited guest
research fellow, laboratory of Professor Richard N Bergman at the
University of Southern California, Keck School of Medicine, LA and
an industrial research fellow at Novo Nordisk A/S Bagsvaerd Denmark
& University of Copenhagen, Denmark. Additionally, she
completed her postdoctoral research fellowship at the University
Department of Medicine, Edinburgh Scotland and Université
Catholique de Louvain.
Dr. Cox added, “Dr. Kjems is a strong addition to the Cyclo
Therapeutics team. With my transition to the SAB, I am pleased to
continue working alongside Dr. Kjems and the incredible team at
Cyclo Therapeutics with the united vision to provide patients and
families with life-changing medicines for the treatment of rare
diseases where there remains significant unmet need. Having worked
closely with the Company over the course of this year, I have even
more confidence that Trappsol® Cyclo™ has a real opportunity to
make a valuable impact on the lives of patients and their
families.”
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793. NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005191/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2023 to Apr 2024